DDInter785 DDInter782
Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA. Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018]
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Fostamatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Fostamatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ripretinib
Fostamatinib {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Fostamatinib {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Fostamatinib may lead to a major life threatening interaction when taken with Clarithromycin
Fostamatinib may lead to a major life threatening interaction when taken with Berotralstat